# Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
Canonical URL: https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-closure-of-naval-1-clinical-trial-and-exploration-of-strategic-alternatives
Ticker: VIRX
Company: Viracta Therapeutics
Source: Viracta Therapeutics
Published: 2024-12-26 21:30 EST
Original Source URL: https://viracta.investorroom.com
## Article Body
No article body is available yet.
## Recent Company News
- 2025-02-05 22:00 EST — [Viracta Therapeutics Announces Wind Down of Operations](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-wind-down-of-operations) — Source: Viracta Therapeutics
- 2024-12-26 21:30 EST — [Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-closure-of-naval-1-clinical-trial-and-exploration-of-strategic-alternatives) — Source: Viracta Therapeutics
- 2024-11-13 12:00 EST — [Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update) — Source: Viracta Therapeutics
- 2024-11-06 20:19 EST — [Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-announces-reprioritization-of-resources-to-enhance-focus-on-nana-val-development-program-in-patients-with-relapsed-or-refractory-ebv-positive-peripheral-t-cell-lymphoma) — Source: Viracta Therapeutics
- 2024-09-05 15:32 EST — [Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference](https://biopharmsignal.com/news/VIRX/viracta-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference) — Source: Viracta Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)